| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Methylhydroquinone has a role as an angiogenesis inhibitor, an anti-inflammatory agent, and a Penicillium metabolite. It inhibits the growth of endothelial and tumor cells in culture in the micromolar range. Its targets include pathways involved in angiogenesis and tumor growth.
|
|---|---|
| ln Vitro |
In vitro, Methylhydroquinone inhibits the growth of endothelial and tumor cells in culture in the micromolar range. It is a promising drug candidate in the treatment of cancer and other angiogenesis-related pathologies. It acts as a reducing agent and a polymerization inhibitor.
|
| ln Vivo |
In vivo, Methylhydroquinone has potential applications in cancer treatment and anti-angiogenesis therapy. Its anti-inflammatory properties also suggest potential for inflammatory diseases. Animal studies are needed to confirm its in vivo efficacy and safety.
|
| Enzyme Assay |
Cell-free assays for Methylhydroquinone involve angiogenesis inhibition studies. The compound is tested in endothelial cell proliferation, migration, and tube formation assays. Anti-inflammatory activity is assessed by measuring inhibition of inflammatory mediators. Antioxidant activity is measured using DPPH or ABTS assays.
|
| Cell Assay |
Cellular assays for Methylhydroquinone use endothelial cells and tumor cells. Cells are treated with Methylhydroquinone at concentrations of 0.1-100 µM for 24-72 hours. Cell viability is measured by MTT or CellTiter-Glo assays. Angiogenesis is assessed by tube formation assays on Matrigel. Anti-inflammatory effects are evaluated by measuring cytokine production.
|
| Animal Protocol |
In vivo animal studies for Methylhydroquinone have not been extensively reported. Based on its anti-angiogenic and anti-tumor activity, xenograft mouse models of cancer could be used. Animals would be administered Methylhydroquinone, and tumor growth and angiogenesis would be assessed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Methylhydroquinone are not extensively characterized. Molecular weight: 124.14. Melting point: 128-130°C. Solubility: 77 g/L. Storage: below +30°C. Appearance: white to light yellow powder.
|
| Toxicity/Toxicokinetics |
Comprehensive toxicity data for Methylhydroquinone are limited. As a chemical intermediate, it may have toxicity at high doses. It is for research use only and not approved for clinical use. Standard laboratory safety precautions should be followed.
|
| References | |
| Additional Infomation |
Toluquinol belongs to the hydroquinone class of compounds, in which a hydrogen atom on the benzene ring is replaced by a methyl group. It exhibits anti-angiogenic, anti-inflammatory, and pharmacokinetic activity, and can be used as a metabolite of Penicillium. Methylhydroquinone has been reported in Botryosphaeria berengeriana, Hydropisphaera erubescens, and other organisms with available data.
Methylhydroquinone is a research compound with potential applications in cancer, angiogenesis, and anti-inflammatory research. It is a promising drug candidate for angiogenesis-related pathologies. The compound is available from chemical suppliers. No clinical trials or FDA approvals have been reported. |
| Molecular Formula |
C7H8O2
|
|---|---|
| Molecular Weight |
124.14
|
| Exact Mass |
124.052
|
| CAS # |
95-71-6
|
| PubChem CID |
7253
|
| Appearance |
White to off-white solid
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
277.8±20.0 °C at 760 mmHg
|
| Melting Point |
125-128ºC
|
| Flash Point |
140.2±16.4 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.595
|
| LogP |
1.1
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
9
|
| Complexity |
92.9
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
OC1C=C(C)C(O)=CC=1
|
| InChi Key |
CNHDIAIOKMXOLK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C7H8O2/c1-5-4-6(8)2-3-7(5)9/h2-4,8-9H,1H3
|
| Chemical Name |
2-methylbenzene-1,4-diol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 8.0554 mL | 40.2771 mL | 80.5542 mL | |
| 5 mM | 1.6111 mL | 8.0554 mL | 16.1108 mL | |
| 10 mM | 0.8055 mL | 4.0277 mL | 8.0554 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
